At three, six, nine and 12 months following semaglutide initiation, women using hormone therapy experienced approximately 30% greater total body weight loss than the non-hormone therapy users
The conversation is mostly about coordinating timing if you also pursue clinical treatments (filler, Botox, biostimulators)
what differs is who prepares it and how it is regulated
The FDA then has 60 days to decide whether to accept the application for review (called the "filing decision")
The risk may rise with very low calorie intake, low protein intake, inactivity, older age, inflammatory illness, or rapid weight reduction
Many patients can achieve a more significant weight loss and further reduce health concerns like prediabetes, heart disease, high cholesterol, hypertension, or obstructive sleep apnea